Alendronate Sodium 11 Description (B278a11a Alendronat Sodium Image 1)
Binosto
Product Images NDC 17139-400
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Binosto (NDC 17139-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ascend Therapeutics, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Binosto 70mg Label (B278a11a Blister Label1)
Binosto is a prescription effervescent tablet for oral solution containing 70mg of alendronate sodium. This blister pack contains one complete week of treatment, and is only available through prescription by a healthcare provider. Binosto is manufactured for ASCEND Therapeutics in Morristown, NJ.*
Binosto 70mg Carton 4 Tablets (B278a11a Carton 041)
This is a medication label for a weekly 70 mg effervescent tablet of Alendronate Sodium. It is to be stored in a controlled room temperature between 15°C to 30°C (59°F to 86°F) and protected from moisture. Each effervescent tablet contains 9137 mg of the active ingredient. The patient is advised to read the enclosed Medication Guide before use for complete dosage and administration instructions. The label also includes manufacturing information and a note addressed to the pharmacist regarding providing the medication guide to the patient.*
Figure 1 3 Yr Study (B278a11a Figure 1 Placebo 3 Year Study)
The provided text is a figure caption that shows the Cumulative Incidence of Hip Fractures in a three-year study of FIT for patients with Radiographic Vertebral Fracture at Baseline. The graph displays the percentage of Cumulative Incidence for two types of treatments (Placebo and Alendronate Sodium) over time in months.*
Figure 2 Osteoporosis (B278a11a Figure 2 Osteoporosis)
This is a figure displaying the results of osteoporosis treatment studies in postmenopausal women. It shows the increase in Bone Mineral Density (BMD) in the Lumbar Spine, Femoral Neck and Trochanter after taking Alendronate Sodium 10mg/day for three years. The results are presented as a mean percentage increase relative to the placebo, with standard error bars shown for each.*
Figure 3 Osteoporosis (B278a11a Figure 3 Osteoporosis)
The text describes a figure showing the results of two studies on the effect of Alendronate Sodium treatment versus placebo in postmenopausal women with osteoporosis. The results are shown as a percent change in bone mineral density from baseline over time, specifically in the lumbar spine. The figure shows data from both a US-based study and a multinational study. The x-axis of the figure represents time in months and the y-axis represents the percent change in bone mineral density.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
